Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Duska Therapeutics has announced that the company's management and clinical and regulatory consultants met on April 16, 2008, with members of the FDA Division of Cardiovascular and Renal Products to discuss the appropriate regulatory pathway for filing a marketing application of ATPace as an antiarrhythmic drug for the acute termination of paroxysmal supraventricular tachycardia.
Subscribe to our email newsletter
Based on discussions held during the meeting and prior written communications between Duska and the FDA, the company believes that the FDA would consider a new drug application (NDA) under section 505(b)(2) for ATPace subject to additional clinical data to be furnished by the company.
James Kuo, Duska’s Chairman and CEO, said: “Together with our CRO, Cato Research, we have already commenced activities aimed at the generation of the supplemental data requested by the FDA. The 505(b)(2) NDA filing provides an expedited route for potential approval of ATPace.”